Synpromics was proud to be featured at the launch of the inaugural joint report from the Alliance for Regenerative Medicine (ARM) and the UK BioI
Synpromics joined the BSGCT in Sheffield at the end of June to share the latest progress in gene and cell therapy.
David Venables presented to a full room of investors at the ARM Cell & Gene Therapy Investor Day in New York.
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa.